



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono

Virgil Lee Beaston
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhullier
Rae Lynn Prensaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Daniel A. Klein
Rodney G. Maze
Jason D. Eisenberg
Michael A. Specht
Andrea J. Kamage
Tracy L. Muller

Jon E. Wright
LuAnne M. Yuricek

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
John J. Figueroa

1647
Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
W. Brian Edge

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
*Practice Limited to
Federal Agencies

February 26, 2003

WRITER'S DIRECT NUMBER:

(202) 772-8615

INTERNET ADDRESS:

FRANKC@SKGF.COM

RECEIVED

MAR 04 2003

Art Unit 1647

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 09/380,704; § 102(e) Date: June 6, 2000
For: **Identification of Agents for Use in the Treatment of Alzheimer's Disease**
Inventors: Bush *et al.*
Our Ref: 0609.4350001/JAG/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fee Transmittal Form (PTO/SB/17);
2. Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(1);
3. Amendment and Reply Under 37 C.F.R. § 1.111 along with Exhibits 1 and 2;
4. A paper copy of a sequence listing;
5. A computer readable copy of the sequence listing;
6. Copies of the following postcards previously stamped and dated by the PTO:
January 18, 2000, March 14, 2000, August 14, 2000, November 30, 2000,
December 27, 2000, January 16, 2001, and February 15, 2001;
7. Form PTO-2038 Credit Card Payment Form in the amount of **\$465.00** to cover the extension of time fee; and
8. Return postcard.

Commissioner for Patents
February 26, 2003
Page 2


In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

FRC/pcd
Enclosures

::ODMA\MHODMA\SKGF_DC1;105934;1

FEB 26 2003

**FEE TRANSMITTAL
for FY 2003**

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$465.00)****Complete if Known**

Application Number	09/380,704
§ 102(e) Date	June 6, 2000
First Named Inventor	Ashley I. Bush
Examiner Name	Bunner, B.
Group Art Unit	1647
Attorney Docket No.	0609.4350001/JAG/FRC

METHOD OF PAYMENT (check all that apply)☐ Check ☒ Credit card ☐ Money Order ☒ Other** ☐ None☐ Deposit Account

Deposit Account Number 19-0036

Deposit Account Name: Sterne, Kessler, Goldstein & Fox P.L.L.C.

The Commissioner is authorized to: (check all that apply)☒ Charge fee(s) indicated below ☒ Credit any over payments☒ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

** Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1105	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Extra	Fee from below	Fee Paid
-------	----------------	----------

Total Claims _____ - 20** = _____ X _____ = _____

Indep. Claims _____ - 3** = _____ X _____ = _____

Multiple Dependent _____ = _____

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissue, see above

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1051	130	2051	65	Surcharge - late filing fee or oath
1502	50	2052	25	Surcharge-late provisional filing fee or cover sheet
1053	130	1053	130	Non-English specification
1812	2,520	1812	2,520	For filing a request for ex parte reexamination
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1251	110	2251	55	Extension for reply within first month
1252	410	2252	205	Extension for reply within second month
1253	930	2253	465	Extension for reply within third month
1254	1,450	2254	725	Extension for reply within fourth month
1255	1,970	2255	985	Extension for reply within fifth month
1401	320	2401	160	Notice of Appeal
1402	320	2402	160	Filing a brief in support of an appeal
1403	280	2403	140	Request for oral hearing
1451	1,510	1451	1,510	Petition to institute a public use proceeding
1452	110	2452	55	Petition to revive - unavoidable
1453	1,300	2453	650	Petition to revive - unintentional
1501	1,300	2501	650	Utility issue fee (or reissue)
1502	470	2502	235	Design issue fee
1503	630	2503	315	Plant issue fee
1460	130	1460	130	Petitions to the Commissioner
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)
1806	180	1806	180	Submission of Information Disclosure Stmt
8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))
1801	750	2801	375	Request for Continued Examination (RCE)
1802	900	1802	900	Request for expedited examination of a design application

Other fee (specify) _____

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$465.00)**SUBMITTED BY**

Name (Print/Type)

Frank R. Cottingham

Registration No.
(Attorney/Agent)

50,437

Complete (if applicable)

Telephone 202-371-2600

Signature

Frank R. Cottingham


Date

FEB. 26, 2003


WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Applicant: BUSH *et al.*



Due Date: N/A

Art Unit: To Be Assigned

Examiner: To Be Assigned

Docket: 0609.4350001

Atty: REF/KKV

Application No.: 09/380,704

Filed: September 8, 1999

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Transmittal Letter (*in duplicate*); (*in duplicate*)
2. Information Disclosure Statement;
3. Form PTO-1449 (33 sheets citing 186 documents);
4. 121 documents attached (AA1, AB1, AC1, AF1, AG1, AI1, AK1, AL1, AM1, AN1, AI2, AJ2, AK2, AN2, AO2, AI3, AK3, AL3, AI4, AJ4, AK4, AP4, AI5, AJ5, AL5, AM5, AN5, AO5, AP5, AL6, AM6, AN6, AP6, AL7, AM7, AN7, AO7, AP7, AL8, AN8, AL9, AO9, AP9, AL10, AM10, AO10, AP10, AL11, AN11, AL12, AP12, AL13, AN13, AO13, AP13, AL14, AM14, AP14, AN15, AO15, AP15, AL16, AM16, AN16, AO16, AL17, AN17, AO17, AN18, AO18, AL19, AM19, AN19, AO19, AP19, AL20, AN20, AP20, AM21, AO21, AP21, AM22, AN22, AM23, AO23, AP23, AM24, AN24, AO24, AP24, AL25, AM25, AN25, AO25, AP25, AL26, AM26, AP26, AN27, AO27, AP27, AM28, AN28, AO28, AP28, AL29, AM29, AN29, AO29, AP29, AL30, AP30, AL31, AM31, AP31, AL32, AM32, AL33, AM33, AN33 and AO33); and
5. One (1) return postcard.

Applicant: Bush *et al.*

Application No.: 09/380,704

Filed: September 8, 1999

For:



Art Unit: To be assigned


Examiner: To be assigned

Docket: 0609.4350001

Atty: REF /KKV

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Transmittal letter (in duplicate);
2. First Supplemental Information Disclosure Statement (in duplicate);
3. 2 sheets of Form PTO-1449 citing 3 documents; and
4. A copy of each of the 3 documents cited thereon.



Applicant: Bush *et al.*

Application No.: 09/380,704

Filed: June 6, 2000

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease


Due Date: None

Art Unit: 1614

Examiner: To be assigned

Docket: 0609.4350001

Atty: REF/KKV



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. PTO Transmittal Letter (*in duplicate*);
2. Second Supplemental Information Disclosure Statement (*in duplicate*);
3. A list of the cited references on Form PTO-1449 (5 sheets);
4. A copy of each cited reference on Form PTO-1449 (24 references); and
5. One (1) Return Postcard.



Please Date Stamp And Return To Our Courier

Applicant: Bush *et al.*

Application No.: 09/380,704

102(e) Date: June 6, 2000

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease

Due Date: None

Art Unit: 1614

Examiner: To be assigned

Docket: 0609.4350001

Atty: JAG/HLK



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Third Supplemental Information Disclosure Statement (*in duplicate*);
2. A list of cited documents on Form PTO-1449 (1 sheet);
3. A copy of each document cited on Form PTO-1449 (5 documents); and
4. One (1) Return Postcard.



Please Date Stamp And Return To Our Courier

Applicants: Bush *et al.*

Application No.: 09/380,704

102(e) Date: June 6, 2000

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease


Due Date: None

Art Unit: 1614

Examiner: To Be Assigned

Docket: 0609.4350001

Atty: JAG/KKV



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Fourth Supplemental Information Disclosure (*in duplicate*);
2. PTO Form 1449 listing the cited documents (1 sheet);
3. A copy of each cited document (5 documents); and
4. One return postcard.

Please Date Stamp And Return To Our Courier



Applicant: Bush *et al.*

Application No.: 09/380,704

102(e) Date: June 6, 2000

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease


Due Date: None

Art Unit: 1614

Examiner: To be assigned

Docket: 0609.4350001

Atty: JAG/KKV



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Fifth Supplemental Information Disclosure Statement (*in duplicate*);
2. A list of the cited references on Form PTO-1449 (1 sheet);
3. A copy of each cited reference on Form PTO-1449 (3 references); and
4. One (1) return postcard.

Please Date Stamp And Return To Our Courier



Applicant: Bush *et al.*

Application No.: 09/380,704

§ 102(e) Date: June 6, 2000

For: Identification of Agents for Use in the Treatment of Alzheimer's Disease

Due Date: None

Art Unit: 1614

Examiner: To be assigned

Docket: 0609.4350001

Atty: JAG/KKV



When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. PTO Transmittal Letter (*in duplicate*);
2. Sixth Supplemental Information Disclosure Statement (*in duplicate*);
3. A list of the cited reference on Form PTO-1449 (1 sheet);
4. A copy of the cited reference on Form PTO-1449 (1 reference); and
5. One (1) Return Postcard.



Please Date Stamp And Return To Our Courier